Tech Company Financing Transactions
Sage Therapeutics Funding Round
Arch Venture Partners and Third Rock Ventures invested in a $20 million Series B funding round for Sage Therapeutics. The round closed on 10/16/2013.
Transaction Overview
Company Name
Announced On
10/16/2013
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Arch Venture Partners (Robert Nelsen)
Third Rock Ventures (Kevin Starr)
Proceeds Purpose
The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE's pipeline programs in CNS disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Sage Therapeutics' (NASDAQ: SAGE) mission is to make life better for patients with nervous systems diseases by discovering, developing, and delivering important new medicines to the market.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Jonas
Chief Financial Officer
Kimi Iguchi
Chief Medical Officer
Stephen Kanes
Chief Scientific Officer
Albert Robichaud
VP - Bus. Development
Michael Cloonan
VP - General Counsel
Anne Marie
VP - Human Resources
Erin Lanciani
VP - Operations
Heinrich Schlieker
VP - R & D
James Doherty
VP - Regulatory Affairs
Amy Schacterle
Browse more venture capital transactions:
Prev: 10/16/2013: Triumfant venture capital transaction
Next: 10/16/2013: Kii venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs